Britain said on Friday it was cutting the cost of COVID-19 tests for travel from the National Health Service (NHS) and was reviewing the list of private providers to ensure pricing is transparent, warning it would clamp down on misleading pricing.
Testing is free for people with symptoms of COVID-19 but all tests used for travel have to be purchased.
Related: UK Regulator To Investigate Pricing Of Covid Tests For Travel
The travel industry, which has been hammered by the pandemic, has long complained that the costs of tests are too high.
The United Kingdom operates a “traffic light” system for international travel, with low-risk countries rated green for quarantine-free travel, medium risk countries rated amber, and red countries requiring arrivals to spend 10 days in isolation in a hotel.
People arriving from green and amber-list destinations must take at least one such test to avoid fines of up to 2,000 pounds ($2,773).
The Department of Health and Social Care said the cost of NHS travel tests will be reduced from 88 pounds to 68 pounds for arrivals from green list countries or fully vaccinated arrivals from amber list countries and from 170 pounds to 136 pounds for two tests for arrivals from amber countries who are not fully vaccinated.
“I know how much people have looked forward to their summer holidays and that the cost of PCR testing can be a barrier to that. That is why I am determined to protect consumers and hardworking families from exploitative practices and ensure high quality tests are available at a reasonable price,” said health minister Sajid Javid.
Last week Britain’s competition regulator, the Competition and Markets Authority (CMA), began a review of the COVID-19 tests market following a request from Javid.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world. UK Lowers Cost Of COVID-19
Featured News
Judge Appoints Law Firms to Lead Consumer Antitrust Litigation Against Apple
Dec 22, 2024 by
CPI
Epic Health Systems Seeks Dismissal of Antitrust Suit Filed by Particle Health
Dec 22, 2024 by
CPI
Qualcomm Secures Partial Victory in Licensing Dispute with Arm, Jury Splits on Key Issues
Dec 22, 2024 by
CPI
Google Proposes Revised Revenue-Sharing Limits Amid Antitrust Battle
Dec 22, 2024 by
CPI
Japan’s Antitrust Authority Expected to Sanction Google Over Monopoly Practices
Dec 22, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – CRESSE Insights
Dec 19, 2024 by
CPI
Effective Interoperability in Mobile Ecosystems: EU Competition Law Versus Regulation
Dec 19, 2024 by
Giuseppe Colangelo
The Use of Empirical Evidence in Antitrust: Trends, Challenges, and a Path Forward
Dec 19, 2024 by
Eliana Garces
Some Empirical Evidence on the Role of Presumptions and Evidentiary Standards on Antitrust (Under)Enforcement: Is the EC’s New Communication on Art.102 in the Right Direction?
Dec 19, 2024 by
Yannis Katsoulacos
The EC’s Draft Guidelines on the Application of Article 102 TFEU: An Economic Perspective
Dec 19, 2024 by
Benoit Durand